2,226 research outputs found
Depression, anxiety, substance misuse and self-harm in children and young people with rare chronic liver disease
The burden of mental illness in young people with chronic liver disease is not known. In this population cohort study in England, we identified 358 individuals (aged ≤25 years) diagnosed with autoimmune hepatitis or liver disease related to cystic fibrosis and 1541 propensity-score-matched controls. By the first year of follow-up, the cumulative burden of psychiatric events in participants with liver disease was high compared with controls: anxiety disorder (6.87 per 100 individuals [95% CI 4.00-9.73] v. 2.22 [95% CI 1.37-3.07]), depression (5.10 [95% CI 2.83-7.37] v. 0.86 [95% CI 0.53-1.19]), substance misuse (10.61 [95% CI 9.50-11.73] v. 1.23 [95% CI 0.71-1.75]) and self-harm (3.09 [95% CI 1.12-5.05] v. 0.20 [95% CI 0.07-0.33]). Participants with liver disease had a 2-fold increase (OR = 1.94, 95% CI 1.45-2.58), a 2.5-fold increase (OR = 2.59, 95% CI 1.91-3.50) and 4.4-fold increase (OR = 4.44; 95% CI 3.46-5.71) in the risk of anxiety, depression and substance misuse, respectively. These findings highlight the need for effective intervention in psychiatric disorders in young people with rare liver disease
The prevalence of hepatitis C virus among people of South Asian origin in Glasgow: results from a community based survey and laboratory surveillance
Background South Asians often present late with HCV or HBV related liver disease which could have been avoided with early diagnosis and subsequent treatment; however the prevalence of HCV/HBV among South Asians in Glasgow is not known. Accordingly, to inform the need for case finding among this group we aimed to examine the prevalence of Hepatitis C virus (HCV) among South Asians living in Glasgow. Methods A community-based survey recruited individuals at six mosques and four community centres serving the South Asian community during 2009-2010; participants had predominantly never been HCV tested. Laboratory surveillance data involving all individuals tested for HCV during 1993-2009 were examined and South Asians were identified using Nam Pehchan software. Results In the community-based survey, 2.6% of 1288 participants tested HCV-antibody positive; the prevalence ranged from 0.6% among those born in the UK to 3.1% among those born in Pakistan. The odds of testing HCV-antibody positive were significantly raised among those who had surgery in South Asia (aOR: 5.0, 95% CI: 2.0-12.3) and had either medical/dental treatment or an injection in South Asia (aOR: 2.2, 95% CI: 1.0-5.0). Of 6404 South Asians identified from laboratory surveillance data, 9.3% tested HCV positive. An estimated 38% (330/870) of HCV-infected South Asians living in Glasgow remain undiagnosed. Conclusions South Asians living in Glasgow, particularly those born outside the UK are at greater risk of HCV infection than the general population. Efforts to increase awareness and testing in this population are warranted.</p
Bridging the gap between low and high mass dwarf galaxies
While the dark matter content within the most massive giant and smallest
dwarf galaxies has been probed -- spanning a range of over one million in mass
-- an important observational gap remains for galaxies of intermediate mass.
This gap covers K band magnitudes of approximately -16 > M_K > -18 (for which
dwarf galaxies have B--K ~ 2). On the high mass side of the gap are dwarf
elliptical (dE) galaxies, that are dominated by stars in their inner regions.
While the low mass side includes dwarf spheroidal (dSph) galaxies that are dark
matter-dominated and ultra compact dwarf (UCD) objects that are star-dominated.
Evolutionary pathways across the gap have been suggested but remain largely
untested because the `gap' galaxies are faint, making dynamical measurements
very challenging. With long exposures on the Keck telescope using the ESI
instrument we have succeeded in bridging this gap by measuring the dynamical
mass for five dwarf galaxies with M_K ~ -17.5 (M_B ~ --15.5). With the
exception of our brightest dwarf galaxy, they possess relatively flat velocity
dispersion profiles of around 20 km/s. By examining their 2D scaling relations
and 3D fundamental manifold, we found that the sizes and velocity dispersions
of these gap galaxies reveal continuous trends from dE to dSph galaxies. We
conclude that low-luminosity dwarf elliptical galaxies are dominated by stars,
not by dark matter, within their half light radii. This finding can be
understood if internal feedback processes are operating most efficiently in gap
galaxies, gravitationally heating the centrally-located dark matter to larger
radii. Whereas external environmental processes, which can strip away stars,
have a greater influence on dSph galaxies resulting in their higher dark matter
fractions. Abridged.Comment: 20 pages, includes 12 figures, accepted for publication in MNRA
Recommended from our members
Adeno-associated virus-8-Mediated intravenous transfer of myostatin propeptide leads to systemic functional improvements of slow but not fast muscle
Myostatin is a member of the transformating growth factor-_ (TGF-_) superfamily of proteins and is produced almost exclusively in skeletal muscle tissue, where it is secreted and circulates as a serum protein. Myostatin acts as a negative regulator of muscle mass through the canonical SMAD2/3/4 signaling pathway. Naturally occurring myostatin mutants exhibit a ‘double muscling’ phenotype in which muscle mass is dramatically increased as a result of both hypertrophy and hyperplasia. Myostatin is naturally inhibited by its own propeptide; therefore, we assessed the impact of adeno associated virus-8 (AAV8) myostatin propeptide vectors when systemically introduced in MF-1 mice. We noted a significant systemic increase in muscle mass in both slow and fast muscle phenotypes, with no evidence of hyperplasia; however, the nuclei-to- cytoplasm ratio in all myofiber types was significantly reduced. An increase in muscle mass in slow (soleus) muscle led to an increase in force output; however, an increase in fast (extensor digitorum longus [EDL]) muscle mass did not increase force output. These results suggest that the use of gene therapeutic regimens of myostatin inhibition for age-related or disease-related muscle loss may have muscle-specific effects
The Structures of Distant Galaxies V: The Evolution of Galaxy Structure in Stellar Mass at z < 1
Galaxy structure and morphology is nearly always studied using the light
originating from stars, however ideally one is interested in measuring
structure using the stellar mass distribution. Not only does stellar mass trace
out the underlying distribution of matter, it also minimises the effects of
star formation and dust on the appearance and structure of a galaxy. We present
in this paper a study of the stellar mass distributions and structures of
galaxies at z<1 as found within the GOODS fields. We use pixel by pixel
K-corrections to construct stellar mass and mass-to-light ratio maps of 560
galaxies of known morphology at magnitudes z_{850}<24. We measure structural
and size parameters using these stellar mass maps, as well as on ACS BViz band
imaging. This includes investigating the structural CAS-Gini-M_{20} parameters
and half-light radius for each galaxy. We compare structural parameters and
half-light radii in the ACS z_{850}-band and stellar mass maps, finding no
systematic bias introduced by measuring galaxy sizes in z_{850}. We furthermore
investigate relations between structural parameters in the ACS BViz bands and
stellar mass maps, and compare our result to previous morphological studies.
Combinations of various parameters in stellar mass generally reveal clear
separations between early and late type morphologies, but cannot easily
distinguish between star formation and dynamically disturbed systems. We also
show that while ellipticals and early-type spirals have fairly constant CAS
values at z<1 we find a tendency for late-type spiral and peculiar
morphological types to have a higher A(M_{*}) at higher redshift. We argue that
this, and the large fraction of peculiars that appear spiral-like in stellar
mass maps, are possible evidence for either an active bulge formation in some
late-type disks at z<1 or the presence of minor merger events.Comment: 27 pages, MNRAS in pres
Stat2 loss disrupts damage signalling and is protective in acute pancreatitis
The severity of sterile inflammation, as seen in acute pancreatitis, is determined by damage-sensing receptors, signalling cascades and cytokine production. Stat2 is a type I interferon signalling mediator that also has interferon-independent roles in murine lipopolysaccharide-induced NF-κB-mediated sepsis. However, its role in sterile inflammation is unknown. We hypothesised that Stat2 determines the severity of non-infective inflammation in the pancreas. Wild type (WT) and Stat2-/- mice were injected intraperitoneally with caerulein or L-arginine. Specific cytokine-blocking antibodies were used in some experiments. Pancreata and blood were harvested 1 h and 24 h after the final dose of caerulein and up to 96 h post L-arginine. Whole-tissue phosphoproteomic changes were assessed using label-free mass spectrometry. Tissue-specific Stat2 effects were studied in WT/Stat2-/- bone-marrow chimera and using Cre-lox recombination to delete Stat2 in pancreatic and duodenal homeobox 1(Pdx1)-expressing cells. Stat2-/- mice were protected from caerulein- and L-arginine-induced pancreatitis. Protection was independent of type I interferon signalling. Stat2-/- mice had lower cytokine levels including TNFα and IL-10 and reduced NF-kB nuclear localisation in pancreatic tissue compared to WT. Inhibition of TNFα improved (inhibition of IL-10 worsened) caerulein-induced pancreatitis in WT but not Stat2-/- mice. Phosphoproteomics showed down-regulation of mitogen-activated protein kinase (MAPK) mediators but accumulation of Ser412-phosphorylated Tak1. Stat2 deletion in Pdx1-expressing acinar cells (Stat2flox/Pdx1-cre ) reduced pancreatic TNFα expression, but not histological injury or serum amylase. WT/Stat2-/- bone-marrow chimera mice were protected from pancreatitis irrespective of host or recipient genotype. Stat2 loss results in disrupted signalling in pancreatitis, upstream of NF-κB in non-acinar and/or bone marrow derived cells. This article is protected by copyright. All rights reserved
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis – A pooled analysis
AbstractBackground & aimsChronic hepatitis C virus (HCV)-infected patients with cirrhosis are a high-priority population for treatment. To help inform the benefit–risk profile of the all-oral direct-acting antiviral (DAA) combination regimen of ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir (OBV/PTV/r ± DSV) in patients with Child-Pugh A cirrhosis, we undertook a comprehensive review of AbbVie-sponsored clinical trials enrolling patients with Child-Pugh A cirrhosis.MethodsTwelve phase II or III clinical trials of the 2-DAA regimen of OBV/PTV/r ± ribavirin (RBV) or the 3-DAA regimen of OBV/PTV/r + DSV ± RBV that included patients with Child-Pugh A cirrhosis were reviewed; patients who completed treatment by November 16, 2015 were included in a pooled, post hoc safety assessment. The number and percentage of patients with treatment-emergent adverse events (TEAEs), serious TEAEs, and TEAEs consistent with hepatic decompensation were reported.ResultsIn 1066 patients with Child-Pugh A cirrhosis, rates of serious TEAEs and TEAEs leading to study drug discontinuation were 5.3% (95% CI: 4.1–6.8) and 2.2% (95% CI: 1.4–3.2), respectively. Thirteen patients (1.2%; 95% CI: 0.7–2.1) had a TEAE that was consistent with hepatic decompensation. The most frequent TEAEs consistent with hepatic decompensation were ascites (n=8), esophageal variceal hemorrhage (n=4), and hepatic encephalopathy (n=2).ConclusionsThis pooled analysis in 1066 HCV-infected patients with Child-Pugh A cirrhosis confirms the safety of OBV/PTV/r ± DSV ± RBV in this population. These results support the use of OBV/PTV/r ± DSV ± RBV in this high-priority population.Lay summaryThis pooled safety analysis in 1066 HCV-infected patients with compensated cirrhosis, receiving treatment with ombitasvir, paritaprevir, and ritonavir with or without dasabuvir, with or without ribavirin, shows that the rate of hepatic decompensation events was comparable to rates from historical reports for untreated patients
- …